
PRAME suppresses retinoid efficacy in keratinocyte carcinomas (KCs). The study shows PRAME represses epidermal differentiation and retinoid response by recruiting EZH2 to RAREs. High PRAME correlates with poor differentiation, while PRAME depletion restores retinoid sensitivity. Combined EZH2 inhibition and retinoid therapy enhance RARE activation and suppress PRAME-expressing KC growth. Targeting PRAME-EZH2 interactions may overcome retinoid resistance in BCC and SCC treatment.
Like
Save
Share